An experimental oral vaccine has demonstrated potential in preventing invasive bacterial diarrhea caused by Shigella, according to a recent human trial. The infection affects hundreds of thousands of people annually in the U.S.
Shigella causes approximately 450,000 infections each year in the United States. This common cause of diarrheal illness can be particularly dangerous, leading to more severe complications and requiring hospitalization in some cases.
The recent trial involved adults and tested an experimental oral vaccine designed to protect against Shigella infection. Results from this small human trial indicate that the vaccine may offer protection against invasive bacterial diarrhea. Further research and larger trials will likely be needed to confirm these findings and assess the long-term efficacy and safety of the vaccine.
The development of a preventative measure is significant because current treatment primarily focuses on managing symptoms and preventing the spread of infection, rather than preventing it altogether. The potential for an oral vaccine offers a more proactive approach to combating this widespread illness.
We don't rate truth. We strip the spin and show you which perspectives covered the story. You decide.
Read the original coverage
💬 Comments
📜 Comment Policy